-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The risk of gastrointestinal bleeding (GIB) associated with the simultaneous treatment of non-vitamin K oral anticoagulants (NOAC) and oral glucocorticoids is not yet clear
.
Recently, a research article published in Heart, an authoritative journal in the field of cardiology, researchers aimed to investigate the short-term GIB risk after simultaneous treatment with NOAC and glucocorticoids
.
This registration-based Danish national study included patients with atrial fibrillation who took NOACs from 2012 to 2018
.
If the patient is prescribed glucocorticoids within 60 days before the occurrence of GIB, it is defined as oral glucocorticoids
The study included 98376 patients treated with NOACs (median age was 75 years (IQR: 68-82), 44% were women), and 16% of the patients had changed their oral glucocorticoid prescriptions at least once within 3 years
.
Compared with unexposed patients, the HR of GIB increased (daily dose <20 mg, HR was 1.
Compared with patients who only use NOACs, simultaneous treatment with NOACs and oral glucocorticoids is associated with an increased short-term incidence and risk of GIB
Original source:
Anders Holt.
et al.
Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants .
heart.
2021.
Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants in this message
